Research Report Confirms Opportunity For Anavex Life Sciences Corp. (AVXL.OB) Anti-Cancer And Neuropathic Pain Compounds
2/26/2014 9:07:51 AM
NEW YORK, Feb. 26, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds. The article describes that sigma-1 receptor (S1R) modulation prevents neuropathic pain and mitochondrial abnormalities induced by the chemotherapy drug paclitaxel.
Help employers find you! Check out all the jobs and post your resume.
comments powered by